Tavapadon Mechanism of Action: How a D1/D5 Agonist Treats Parkinson's

Tavapadon (brand name Juvmo) is the first FDA-approved Parkinson's drug that selectively targets D1/D5 dopamine receptors. For decades, dopamine agonists have worked mainly through D2/D3 receptors. Here is how tavapadon works, why that matters, and what the Phase 3 TEMPO trials actually showed. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. Zafar, S., Lui, F., & Yaddanapudi, S. S. (2025). Parkinson Disease. In StatPearls. StatPearls Publishing. 2. Martel, J. C., & Gatti McArthur, S. (2020). Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia. Frontiers in pharmacology, 11, 1003. https://doi.org/10.3389/fphar.2020.01003 3. https://www.neurologylive.com/view/fd... 4. Bezard, E., Gray, D., Kozak, R., Leoni, M., Combs, C., & Duvvuri, S. (2024). Rationale and development of tavapadon, a D1/D5-selective partial dopamine agonist for the treatment of Parkinson’s disease. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders), 23(4), 476-487. 5. Li, A., Cha, A., Huang, M., Dhami, S., & Pemminati, S. (2025). A review of the recent advances in the pharmacological management of Parkinson’s disease. Cureus, 17(9). 6. Kaye, A. D., Ford, B. M., Abbott, B. M., Broocks, K. M., Novacic, S., & Shekoohi, S. (2025). Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson's Disease. Diseases (Basel, Switzerland), 13(9), 290. https://doi.org/10.3390/diseases13090290 7. https://www.neurologylive.com/view/un... #Tavapadon #ParkinsonsDisease #Juvmo #Neurology #DopamineAgonist #Parkinsons #FDAApproval #MedicalEducation #Pharmacology #PharmacyEducation #Neuropharmacology #NeurodegenerativeDiseases